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Abstract
Background: The current study was undertaken to characterize the effect of anti-metabolites on inducing CXCL8 signaling
and determining whether the constitutive and/or drug-induced CXCL8 signaling in metastatic prostate cancer (CaP) cells
modulates their sensitivity to this class of agent.
Methods: The response of metastatic CaP cells to 5-Fluorouracil (5-FU), Pemetrexed or Tomudex was determined using cell
count assays, flow cytometry and PARP cleavage analysis. Quantitative-PCR, ELISA and immunoblots were employed to
determine effects of drugs or CXCL8 administration on target gene/protein expression.
Results: Administration of 5-FU but not pemetrexed potentiated CXCL8 secretion and increased CXCR1 and CXCR2 gene
expression in metastatic PC3 cells. Consistent with this, the inhibition of CXCL8 signaling using a CXCR2 antagonist,
AZ10397767, increased the cytotoxicity of 5-FU by 4-fold (P,0.001), and increased 5-FU-induced apoptosis in PC3 cells
(P,0.01). In contrast, while administration of AZ10397767 had no effect on the sensitivity of pemetrexed, the CXCR2
antagonist exerted the greatest effect in increasing the sensitivity of PC3 cells to Tomudex, a directed thymidylate synthase
(TS) inhibitor. Subsequent experiments confirmed that administration of recombinant human CXCL8 increased TS
expression, a response mediated in part by the CXCR2 receptor. Moreover, siRNA-mediated knockdown of the CXCL8-target
gene Bcl-2 increased the sensitivity of PC3 cells to 5-FU.
Conclusions: CXCL8 signaling provides a selective resistance of metastatic prostate cancer cells to specific anti-metabolites
by promoting a target-associated resistance, in addition to underpinning an evasion of treatment-induced apoptosis.
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Introduction
Treatment of advanced castrate-resistant metastatic prostate
cancer (CRPC) remains a significant clinical unmet need. The
recent approval of abiraterone-acetate as a second-line treatment
in CRPC is a major advance, however, this agent which targets the
androgen synthesis pathway provides only a limited improvement
in overall survival and only patients with a good performance
status benefit from its provision [1,2]. Many patients will not meet
the preferential performance status that is optimal for response to
abiraterone. Moreover, many tumours will be resistant to
abiraterone in second-line treatment. Consequently, this mandates
that efforts to expand the armoury of agents available to clinicians
treating CRPC is not relaxed. Such efforts should not be restricted
solely to the discovery of new agents but should exploit our
continuing knowledge of the disease biology to define mechanisms
of resistance and identify novel agents which can be exploited to
improve the efficacy of existing chemotherapy agents.
Conventional chemotherapy has been largely ineffective in the
treatment of CRPC; docetaxel remains the sole chemotherapy
agent to have obtained approval for CRPC, on the basis of a
limited improvement in overall survival [3]. The anti-metabolite 5-
FU has been a mainstay of solid tumor chemotherapy for over five
decades; upon entering the cell, 5-FU is converted to three active
metabolites, fluorouridine triphosphate (FUTP), flurodeoxyuridine
triphosphate (FdUTP) and flurodeoxyuridine monophosphate
(FdUMP), which are mis-incorporated into RNA, promote DNA
damage, or contribute to the inhibition of the enzyme thymidylate
synthase, respectively [4]. Recent phase II studies of 5-FU and its
oral analog capecitabine have shown them to be safe in second-
line treatment for metastatic CRPC, with modest responses
observed when administered in combination with docetaxel or
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responses, the capacity to target rapidly proliferating CaP cells
by inducing an S-phase block and subsequently apoptosis
induction remains an attractive therapeutic scenario, especially
in tumors that have become refractory to anti-androgen therapy.
Prostate cancer cells are subject to a pronounced autocrine
CXCL8signalingstimulus,whichincreaseswithstageofdiseaseand
is maximal in castrate-resistant disease [7,8]. The magnitude of
CXCL8 signaling is potentiated by environmental factors such as
hypoxia [9] and chemically-induced stresses including exposure to
chemotherapy agents [10,11], which concurrently regulate expres-
sion of the ligand and the receptors through which it mediates its
biological effects, i.e. CXCR1 and CXCR2. CXCL8 promotes
progression to castrate-resistance through ligand-independent
activation of the androgen receptor (AR) [12,13] and induces the
proliferation of metastatic prostate cancer cells [7,14] (). Further-
more, we have shown that stress-induced CXCL8 signaling
attenuates the sensitivity of prostate cancer cells to undergo
apoptosis in response to DNA-damaging agents [9,10], Hsp90-
directed inhibitors [15], death receptor agonists (TRAIL) [11] and
AR-targeted therapeutics such as bicalutimide (Casodex) [13].
The aim of this study was to determine how intrinsic and/or
treatment-induced CXCL8 signaling modulates the response of
CRPC cells to anti-metabolites.
Materials and Methods
Chemical and Reagents
All chemicals were source from Sigma-Aldrich (St. Louis, MO)
unless otherwise stated. 5-FU was obtained from Bridgewater
Chemotherapy Suite, Belfast City Hospital. Pemetrexed was a
kind gift from Dr Dean Fennell (CCRCB, QUB, Belfast, UK).
AZ10397767 was kindly provided by Dr. Simon T. Barry and Dr.
David Blakey (AstraZeneca, Alderley Park, Cheshire, UK).
Cell Culture
PC3 prostate cancer cells were cultured as previously described
[10]. In subsequent experiments investigating CXCL8 signaling,
PC3 cells were incubated in serum-free RMPI 1640 medium for
16 h prior to exposure to 3 nM recombinant human (rh)-CXCL8
(Peprotech, London, UK).
Cytotoxic agents
5-FU and pemetrexed were stored at 4uC as 10 mM stock
solutions. Serial dilutions were made up in sterile injection water
and drugs were added directly to cells to yield the desired
concentration of the cytotoxic agent. In the case of 5-FU
treatment, cells were maintained and treated in medium
containing dialysed FCS.
siRNA Transfections
siRNA transfections were carried out as previously described
[11]. Cells (5610
5) were washed twice in sterile PBS and then
incubated with a transfection mixture comprising optimem
medium, oligofectamine (Invitrogen, Paisley, UK), and the specific
oligonucleotide (Bcl-2 200 nM; Dharmacon Inc) for 48 h at 37uC.
A non-targeting sequence was included in these experiments at the
same concentration as the siRNA sequence used.
Cell Count Analysis
Cells (1610
5 cells/well) were allowed to adhere overnight.
Media was replaced with fresh RPMI 1640 medium and treated
with a range of concentrations of 5-FU or pemetrexed in the
absence or presence of AZ10397767 (20 nM). Cells were
incubated at 37uC in a humidified 5% CO2 atmosphere for
72 h, then trypsinized and counted using a CoulterH Z
TM Series
particle count and size analyzer (Beckman Coulter, Miami, FL) as
previously described [10]. Cell numbers were normalized to
control values and statistical analyses of the data performed using
GraphPad PRISM 3.0 software.
Flow Cytometry
Cell-cycle analysis was evaluated by propidium iodide staining
of cells as previously described [10].
Immunoblotting
Whole cell lysates were prepared, resolved and blotted as
described previously [7]. Membranes were washed in Tris-
buffered saline/ 0.1% Tween-20 (TBS-T) then blocked for 1h at
room temperature in 5% bovine serum albumin/TBS-T (BSA/
TBS-T). Membranes were probed with primary antibodies to Bcl2
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), TS (Rockland
Immunochemicals Inc., Gilbertsville, PA) or PARP (eBiosciences
Inc., San Diego, CA, USA). The membranes were washed three
times in TBS-T and then incubated with a horse-radish peroxidase
(HRP)-labelled secondary antibody (GE Healthcare UK Ltd,
Buckinghamshire, UK). Following three washes in TBS-T the
bands were detected using enhanced chemiluminescence (ECL
plus reagents, Amersham Biosciences). Membranes were re-
probed with GAPDH antibody to ensure equal loading (Biogen-
esis, Dorset, UK).
Quantitative real time PCR (qPCR)
RNA was harvested as previously described [9]. For real-time
PCR, 1mg of total RNA was oligo(dT) reverse transcribed using
MMLV-RT (Invitrogen, Paisley, UK) according to the manufac-
turer’s instructions. 50 ng cDNA was mixed with primers (2 nM),
sterile water and SYBR Green PCR mastermix (Roche Diagnos-
tics, Sussex, UK). The primer sequences were as previously
reported [9]. Real-time PCR was carried out in a 96-well plate
using an LC480 light cycler instrument (Roche Diagnostics). The
threshold cycle (CP) was calculated for each reaction by the LC480
system. Unknown expression levels were determined using the
relative standard curve method and normalised against 18S.
ELISA
The amount of secreted CXCL8 detected in the medium of
prostate cancer cells was determined using an ELISA assay
according to the manufacturer’s instructions (Pelikine Compact
CXCL8 ELISA kit, Beckman Coulter, High Wycombe, UK) as
previously described [9]. The CXCL8 concentration in each
sample was calculated by comparison to a standard curve
generated from a stock vial of CXCL8.
Results
5-FU potentiates chemokine signaling in metastatic CaP
cells
The PC3 cell line was originally isolated from a bone metastasis
of CaP and therefore is considered to be a clinically-relevant
model system to study advanced CaP [16]. Since prior studies
have shown chemotherapy agents induce CXCL8 synthesis, our
initial experiments focused on characterizing the effects of
administering anti-metabolites upon the secretion of this chemo-
kine. In addition to using 5-FU, our initial experiments were also
conducted using pemetrexed, a multi-targeted anti-folate which
inhibits thymidylate synthase (TS), dihydrofolate reductase
CXCL8 Signalling Antagonizes TS-Targeted Agents
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(GARFT), all enzymes involved in the de novo biosynthesis of
thymidine and purine nucleotides [17]. A specific ELISA was used
to quantify CXCL8 secretion from PC3 cells over an 8 h
timecourse, comparing time-matched controls from 5-FU-treated
or pemetrexed-treated cells. Administration of 5-FU promoted a
significant increase in CXCL8 secretion from PC3 cells (P,0.05)
(Figure 1A). However, administration of pemetrexed had negligi-
ble effects on CXCL8 secretion (Figure 1B). To verify our
observations, experiments were repeated in the LNCaP prostate
cancer cell line; addition of 1 mM 5-FU also increased the levels of
CXCL8 secreted from this cell line (Figure 1C).
The effects of 5-FU and pemetrexed administration upon
expression of the CXCL8 receptors were also studied using
quantitative PCR analysis. Administration of 5-FU had pro-
nounced and sustained effects upon the gene expression of both
CXCR1 (Figure 2A, left panel) and CXCR2 (Figure 2B, left
panel), increasing transcript levels by factors of 8- and 15-fold,
respectively. In contrast, administration of pemetrexed had a
transient and minimal effect upon the gene expression of either
receptor. Further experiments confirmed that 5-FU administration
also increased CXCR1 and CXCR2 transcript levels in LNCaP
cells (Figure 2A/B, right panels), though the response was
markedly more selective for CXCR2 in this cell line.
Inhibition of CXCL8 signaling potentiates 5-FU efficacy in
metastatic CaP cells
Cell count assays were employed to characterize the relative
cytotoxicity of 5-FU or pemetrexed in PC3 cells and to determine
whether drug-induced or intrinsic CXCL8 signaling affected the
sensitivity to these agents. Inhibition of CXCL8 signaling was
effected using a selective CXCR2 receptor antagonist,
AZ10397767. PC3 cells were only sensitive to 5-FU at concen-
trations exceeding 1 mM (Figure 3A). The addition of
AZ10397767, used at a final concentration of 20 nM in order to
exercise its selectivity for the CXCR2 receptor increased the
potency of 5-FU-induced cytotoxicity in PC3 cells. Non-linear
regression analysis of the data confirmed that the inhibition of
CXCR2 signaling enhanced the potency of 5-FU by 3.8-fold,
increasing the calculated IC30 value from 4.2 mM to 1.1 mM
(n=4). Further analysis of the data determined that the addition of
AZ10397767 to 5-FU was synergistic by a calculated RI value of
1.2, while ANOVA analysis confirmed a strong synergistic
interaction between 5-FU and AZ10397767 (P,0.0001). Similar-
ly, the administration of AZ10397767 increased the sensitivity of
LNCaP cells to 5-FU. Repression of CXCR2 signaling had no
effect in increasing the maximal response of 5-FU therapy in either
cell line. In contrast, the administration of the CXCR2 antagonist
did not increase the potency or the maximal response of
pemetrexed in the PC3 cells (Supplementary Figure S1). The
potency of pemetrexed in these assays was calculated as 0.27 mM.
As an additional validation of our results obtained with the
CXCR2 antagonist, we employed a siRNA-strategy to repress
receptor expression. Despite using commercial sequences claiming
to be selective for CXCR1 or CXCR2 knockdown, subsequent
RT-PCR analysis determined significant down-regulation of the
reciprocal receptor in the PC3 and LNCaP cells. Irrespective,
down-regulation of CXCR1 and CXCR2 expression resulted in a
greater loss of PC3 and LNCaP cell viability in the presence of
1 mM 5-FU (Figure 3B).
Flow cytometry analysis confirmed that the inhibition of
CXCR2 signaling potentiated 5-FU-induced apoptosis in both
PC3 and LNCaP cells. Relative to untreated control cells, an
increase in the concentration of 5-FU from 1 mMt o1 0 mM
resulted in an increased accumulation of cells in the S phase of the
cell cycle (Supplementary Figure S2) and the detection of an
increased percentage of cells in the sub G0/G1 phase (Figure 3C).
Addition of AZ10397767 alone to PC3 cells had no observed effect
Figure 1. Effects of anti-metabolite agents upon CXCL8
secretion from prostate cancer cells. (A) Bar graph plotting the
level of CXCL8 secretion following treatment of PC3 cells with 1 mM5 -
FU. Values shown are plotted relative to a time-matched control and
represent the mean 6 S.E.M. of three independent experiments. (B)A s
in A, except that cells were treated with 1 mM pemetrexed. Differences
in CXCL8 expression between time-matched control and drug-treated
samples were analyzed by a two-tailed Student’s t-test; *, p,0.05. (C)
Bar graph plotting the levels of CXCL8 secretion following treatment of
LNCaP cells with 1 mM 5-FU. Values shown are plotted relative to a time-
matched control and represent the mean 6 S.E.M. of three
independent experiments.
doi:10.1371/journal.pone.0036545.g001
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when combined with 1 mM 5-FU, AZ10397767 decreased the
accumulation of the cells arrested in the S phase of the cell cycle
while concurrently increasing the level of apoptotic cells observed
(p,0.0045) (Supplementary Figure S2).
CXCL8 signaling promotes a target-associated resistance
to 5-FU
Thymidylate synthase (TS) expression is a key determinant of 5-
FU sensitivity [18,19]. The increased sensitivity of cells to 5-FU
following the repression of CXCL8 signaling prompted us to
investigate whether CXCL8 signaling regulated the expression of
this enzyme in CaP cells. PC3 cells and LNCaP cells were each
stimulated with 3 nM recombinant-human CXCL8 (rh-CXCL8)
for a maximum of 8 h. TS gene expression was initially analyzed
by quantitative PCR; which confirmed an increase in excess of 4-
fold in both cell lines following stimulation with rh-CXCL8
(Figure 4A). Expression of the TS enzyme was also analysed by
immunoblotting. Stimulation with rhCXCL8 over a short time-
course confirmed an immediate increase in the expression of TS in
PC3 cells (Figure 4B). Furthermore, consistent with the increase in
mRNA transcript levels, we observed a later response to CXCL8
administration, where TS expression levels were shown to increase
at time points out to 8 h in PC3 cells (Figure 4C, left panel) and
LNCaP cells (Figure 4C, right panel).
We next examined how inhibition of CXCR2 signaling affected
TS expression. The addition of AZ10397767 to PC3 cells
attenuated the CXCL8-induced increase in TS gene transcript
levels (Figure 5A) and reduced CXCL8-promoted increases in TS
protein (Figure 5B). Given the association of CXCL8 and CXCR2
to the regulation of TS expression, we examined the effect of
CXCL8 signaling upon the efficacy of Tomudex (TDX), a potent
inhibitor and TS-directed therapeutic. PC3 cells were markedly
insensitive to TDX even at high concentrations of the drug.
However, as observed with 5-FU, the potency of TDX was
markedly increased by the co-administration of the CXCR2
antagonist AZ10397767 (Figure 5C, left panel). Non-linear
regression analysis of the cell count data confirmed that the
potency (IC30) of TDX was increased by 37-fold, from 1.1 mMt o
30 nM in the presence of AZ10397767. The interaction between
AZ10397767 and TDX was strongly synergistic, determined using
two methods of statistical analysis (RI=1.4, ANOVA P,0.0001).
Our data also shows that the maximal response to TDX is
marginally increased in the presence of the CXCR2 antagonist. In
Figure 2. Effects of anti-metabolite agents upon the gene expression of CXCL8 receptors in prostate cancer cells. (A) Bar graph
presenting the time-dependent change in CXCR1 transcript levels in PC3 cells (left panel) and LNCaP cells (right panel) as detected by qPCR analysis
following treatment with 1 mM 5-FU (black bars) or 1 mM Pemetrexed (open bars – PC3 cells only). Expression is presented as a fold-change relative to
gene expression levels detected in untreated cells. (B) As in A, except that data shows the gene expression level detected for CXCR2. Data shown is
the mean 6 S.E.M. of four independent experiments. Statistically significant differences were determined using a Students two-tailed t-test
(*, p,0.05).
doi:10.1371/journal.pone.0036545.g002
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and accordingly, the sensitivity could not be enhanced further by
addition of the CXCR2 antagonist (Figure 5C, right panel).
Inhibition of Bcl-2, a downstream CXCL8-transcriptional
target sensitizes CaP cells to 5-FU
CXCL8 signalling increases the expression of several anti-
apoptotic genes including Bcl-2 [10]. A small-interfering RNA
(SiRNA) strategy was employed to inhibit expression of Bcl-2.
Immunoblotting confirmed a high level of endogenous Bcl-2
expression in PC3 cells. Transfection of the cells with a final
concentration of a 50 nM Bcl-2-targeted oligonucleotide (Bcl-2-T)
reduced but did not eliminate Bcl-2 expression in untreated or 5-
FU-treated cell populations. Interestingly, exposure to 5-FU itself
was shown to increase Bcl-2 expression in PC3 cells (Figure 6A).
Down-regulating Bcl-2 alone had a marked impact in promoting
apoptosis in PC3 cells (increasing to 8.5% and P,0.001 relative to
Figure 3. Effect of inhibiting CXCL8/CXCR2 signaling upon the efficacy of anti-metabolites in metastatic prostate cancer cells. (A)
Graphs illustrating cell count assay data, determined from the treatment of PC3 cells (left panel) or LNCaP cells (right panel) with increasing
concentrations of either 5-FU, in the absence or presence of the CXCR2 receptor antagonist, AZ10397767. AZ10397767 was administered at a final
concentration of 20 nM. Cell counts were taken 72 hours post-treatment with the anti-metabolite. Cell count data was analyzed using the non-linear
regression function of GraphPad Prism, using a sigmoidal one-site curve fit equation. Data points shown are the mean 6 S.E.M. value of four
independent experiments. (B) Bar graph illustrating the effect of using siRNA to knockdown CXCR1 and CXCR2 expression upon the cytotoxicity of
1 mM 5-FU in PC3 (left panel) and LNCaP cells (right panel). Data points shown are the mean 6 S.E.M. value of four independent experiments. (C) Bar
graph presenting the level of apoptotic cells in drug-treated PC3 (left panel) and LNCaP (right panel) cell populations. Data shows the sub G0/G1-cell
population determined by flow cytometry analysis following treatment with increasing concentrations of 5-FU, in the absence and presence of the
CXCR2 receptor antagonist, AZ10397767.
doi:10.1371/journal.pone.0036545.g003
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inducing apoptosis, the combined treatment with 1 mM 5-FU and
the Bcl-2 siRNA-oligonucleotides increased the proportion of
apoptotic cells to a mean value of 10.7%, (P,0.01 relative to 5-FU
treatment alone) (Figure 6B). The increased levels of apoptosis
induced by down-regulation of Bcl-2 in the absence and presence
of 5-FU was confirmed by the detection of increased PARP
cleavage in immunoblotting experiments (Figure 6C).
Discussion
CRPC is currently an incurable disease. Although the
emergence of a new generation of androgen signaling pathway
inhibitors (e.g. abiraterone-acetate and MDV3100) for use in
CRPC patients will contribute to improved outcomes for many
patients, it is clear that a more informed use of conventional
chemotherapy agents will be necessary to improve clinical
outcomes for patients for whom these new drugs fail to work. 5-
FU and its oral analog capecitabine have been reported to be safe
as a second-line treatment for metastatic castrate-resistant CaP,
with modest responses observed when administered in combina-
tion with docetaxel or oxaliplatin in small phase II trials [5,6].
Increasing the response to second-line chemotherapy is of
paramount importance in extending overall survival and the
quality-of-life for patients with advanced disease.
In this study we have shown the importance of CXCL8
signaling in underpinning a novel mode of target-associated
resistance that decreases the sensitivity of metastatic CaP cells to 5-
FU. CXCL8 expression is natively elevated in metastatic or CRPC
over normal or benign prostate tissue [7,8,20]. Moreover, we have
confirmed that exposure to 5-FU potentiates this level of CXCL8
signaling by concurrently inducing CXCL8 secretion and up-
regulating CXCR1 and CXCR2 gene expression in metastatic
prostate cancer cells. Importantly, inhibition of the intrinsic and
drug-induced CXCL8 signaling using a small molecule CXCR2
receptor antagonist resulted in a statistically significant increase in
the sensitivity of CRPC cells to 5-FU. While we have exclusively
studied the role of CXCL8 in modulating this response, our
observations using the CXCR2 inhibitor indicate that stress-
induced increases in the additional CXC-chemokines that also
activate the CXCR2 receptor including CXCL1 and CXCL5 will
also likely contribute to therapeutic resistance.
Elevated expression of TS is a well-established biomarker of
decreased 5-FU efficacy in tumours [18,19]. Administration of
either 5-FU or CXCL8 alone was shown to increase TS gene and
protein levels. Stimulation with CXCL8 was shown to promote
two phases of regulation. We observed a rapid increase in TS
expression in response to CXCL8 administration, consistent with
our prior studies characterizing the role of this chemokine in
regulating protein translation [14]. This was followed by a later-
onset increase in protein expression, consistent with the CXCL8-
promoted increase in transcription of the TS gene. Administration
of a CXCR2 antagonist was shown to attenuate the CXCL8-
Figure 4. CXCL8 signaling regulates the expression of thymidylate synthase (TS) in PC3 cells. (A) Bar graph presenting the time-
dependent change in TS transcript levels in PC3 cells (left panel) and LNCaP cells (right panel) as detected by qPCR analysis following treatment with
3 nM rhCXCL8. Expression is presented as a fold-change relative to gene expression levels detected in untreated cells. (B) Immunoblot demonstrating
the effect of administering 3 nM rhCXCL8 upon the level of TS expression in PC3 cells, detected up to 1 h post-stimulation of the cells. (C)
Immunoblot that illustrates the level of TS expression detected in PC3 cells (left panel) and LNCaP cells (right panel) up to 8 h post-stimulation of the
cells with rhCXCL8. Equal protein loading in each of the representative blots shown in (B) and (C) was confirmed by re-probing of the membranes to
detect expression of GAPDH. Statistically significant differences were determined using a Students two-tailed t-test (***, p,0.001).
doi:10.1371/journal.pone.0036545.g004
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Therefore, our data suggests that CXCL8 signaling manifests a
target-associated resistance to 5-FU in CRPC cells by increasing
the expression of TS. This conclusion is further supported by our
observation that the administration of a CXCR2 antagonist had a
profound effect in sensitizing PC3 cells to a direct TS-targeted
inhibitor, Tomudex.
In addition, we propose that CXCL8 signaling may additionally
contribute a cellular resistance to 5-FU by increasing anti-
apoptotic protein expression. Flow cytometry and PARP cleavage
assays demonstrated that the protective action of CXCL8
signaling was mediated by enabling the cells to evade chemother-
apy-induced apoptosis. We have previously demonstrated that
CXCL8 can up-regulate anti-apoptotic expression in CaP cells,
including expression of Bcl-2, and that co-administration of
AZ10397767 can down-regulate chemotherapy-induced expres-
sion of this protein [10,11]. We provide further evidence that the
suppression of Bcl-2 can increase the level of apoptosis in 5-FU-
treated cells. Therefore, CXCL8 signalling may also contribute to
the resistance of CRPC cells to 5-FU by facilitating an increase in
the expression of critical inhibitors of apoptosis.
Our current study reveals a very distinct and drug-specific effect
of anti-metabolites on CXCL8 signaling. While 5-FU inhibits TS
activity, pemetrexed is a multi-targeted inhibitor with effects upon
three folate-dependent enzymes in the thymidine and purine
nucleotide synthesis pathways; TS, dihydrofolate reductase
(DHFR), and glycinamide ribonucleotide formyltransferase
(GARFT) [17]. While 5-FU potentiated CXCL8 secretion and
increased CXCL8 receptor expression in PC3 cells, pemetrexed
had negligible effects on the expression of CXCL8 or its receptors.
Therefore, our observations that the CXCR2 antagonist had no
effect upon the sensitivity of cells to pemetrexed may relate to the
absence of a pemetrexed-induced increase in CXCL8 signaling
and/or reflects that CXCL8 signaling may not regulate the
Figure 5. Inhibition of CXCR2 signaling represses TS expression and sensitizes the response to Tomudex. (A) Bar graph illustrating the
effect of the CXCR2 inhibitor on the CXCL8-promoted increase in TS transcript levels in PC3 cells as detected by qPCR analysis. The inhibitor was
added overnight and cells stimulated with 3 nM rhCXCL8 for 8 h. (B) A representative immunoblot illustrating the impact of the CXCR2 inhibitor
AZ10397767 upon the expression of TS in unstimulated and CXCL8-stimulated conditions. AZ10397767 was added overnight and cells stimulated
with 3 nM rhCXCL8 for 8 h. (C) Graph illustrating the cell count assay data, determined from the treatment of PC3 cells (left panel) and LNCaP cells
(right panel) with increasing concentrations of Tomudex, in the absence or presence of the CXCR2 receptor antagonist, AZ10397767. Cell counts were
taken 72 hours post-treatment with the anti-metabolite. Cell count data was analyzed using the non-linear regression function of GraphPad Prism,
using a sigmoidal one-site curve fit equation. AZ10397767 was administered at a final concentration of 20 nM in all experiments. Data points shown
are the mean 6 S.E.M. value of three independent experiments; *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0036545.g005
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pemetrexed. Although PC3 cells were sensitive and responded
favourably to pemetrexed treatment, phase II studies in patients
have failed to provide encouragement for the use of this agent as a
second line chemotherapy for metastatic CRPC, suggesting that
other resistance mechanisms relevant to this drug are at play in
this disease setting [21,22].
CXCL8 signaling is a major pro-inflammatory signal in
multiple solid tumors including breast and colorectal cancers
[23,24], diseases in which 5-FU is currently used or recommended
as standard-of-care for metastatic disease. Our current observa-
tions suggest that the optimal use of 5-FU may only be realized in
tumors in which pro-inflammatory signaling, and specifically
CXCL8 signaling, is either absent or is repressed during
chemotherapy. Moreover, 5-FU is typically used in combination
with other chemotherapeutic agents. While platinum-based agents
are not routine for the treatment of metastatic CRPC, there is an
increasing use of these agents in second-line treatment of
metastatic CaP patients who have progressed on docetaxel
[6,25]. Since we have now shown that CXCL8 signaling
modulates the sensitivity of metastatic prostate cancer cells to
both 5-FU and oxaliplatin, expression of this chemokine could be
used as a guide to assist in predicting a patient’s response to an
oxaliplatin/5-FU combination. Moreover, administration of
CXCR2-targeted inhibitors may be especially relevant to exploit
as chemo-modulators in any future study of second-line,
platinum/5-FU based treatments for metastatic CaP.
In summary, this study adds to a growing literature that
documents the relevance of intrinsic and stress/treatment-induced
CXC-chemokine signaling in modulating the sensitivity of
metastatic CaP cells to chemotherapeutic agents. We have shown
that CXCL8 signaling attenuates the efficacy of 5-FU and TDX
by a combination of up-regulating anti-apoptotic gene expression
and through a novel target-associated resistance mechanism
involving increased expression of TS.
Supporting Information
Figure S1 Graphs illustrating cell count assay data, determined
from the treatment of PC3 cells with increasing concentrations of
pemetrexed, in the absence or presence of the CXCR2 receptor
antagonist, AZ10397767. AZ10397767 was administered at a final
concentration of 20 nM. Cell counts were taken 72 hours post-
treatment with the anti-metabolite. Cell count data was analyzed
using the non-linear regression function of GraphPad Prism, using
a sigmoidal one-site curve fit equation. Data points shown are the
mean 6 S.E.M. value of four independent experiments.
(TIF)
Figure S2 Graph illustrating the percentage distribution of PC3
cells throughout the cell cycle following treatment with 1 mMo r
10 mM 5-FU, in the absence or presence of the CXCR2 antagonist
AZ10397767. AZ10397767 was administered at a final concen-
tration of 20 nM. Cell cycle profile was analysed 72 hours post-
treatment with 5-FU. Data shown is the mean value, determined
from three independent experiments.
(TIF)
Author Contributions
Conceived and designed the experiments: DW PGJ RW DL. Performed
the experiments: CW PJM. Analyzed the data: CW PJM DW. Contributed
reagents/materials/analysis tools: DL PGJ. Wrote the paper: DW DL.
Critiqued the manuscript: PGJ RW.
References
1. Attard G, Reid AH, de Bono JS (2010) Abiraterone acetate is well tolerated
without the concomitant use of corticosteroids. J Clin Oncol 28: e560–1.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. (2011)
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med
364: 1995–2005.
Figure 6. Repression of Bcl-2 potentiates 5-FU-induced apop-
tosis in metastatic prostate cancer cells. (A) Immunoblot
presenting the expression level of the anti-apoptotic protein Bcl-2 in
PC3 cells transfected with a non-targeting oligonucleotide (Sc) or a
gene-targeted oligonucleotide (Bcl2-T). All oligonucleotides were used
at a final concentration of 50 nM. Expression of Bcl-2 is presented in the
absence or presence of 1 mM 5-FU. (B) Bar graph presenting the
apoptotic cell population determined by flow cytometry analysis in PC3
cells transfected with a non-targeting oligonucleotide (Sc) or a gene-
targeted oligonucleotide (Bcl2-T) at a final concentration of 50 nM, in
the absence or presence of 1 mM 5-FU. Statistically-significant
differences in the apoptosis levels were determined by conducting
two-tailed Student’s t-test analysis; *, P,0.05; **, p,0.01. (C)
Immunoblot presenting the expression and cleavage product of PARP
in PC3 cells transfected with a non-targeting oligonucleotide (Sc) or a
gene-targeted oligonucleotide (Bcl2-T), used at a final concentration of
50 nM, in the absence or presence of 1 mM 5-FU. Equal protein loading
in immunoblots shown in (A) and (C) was confirmed by re-probing the
membranes for expression of GAPDH.
doi:10.1371/journal.pone.0036545.g006
CXCL8 Signalling Antagonizes TS-Targeted Agents
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e365453. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel
plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
N Engl J Med 351: 1502–12.
4. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of
action and clinical strategies. Nature Rev Cancer 3: 330–338.
5. Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, et al. (2009)
Phase II trial of capecitabine in combination with weekly docetaxel for
metastatic castrate resistant prostate cancer. J Urol 182: 317–23.
6. Gasent Blesa JM, Giner Marco V, Giner-Bosch V, Cerezuela Fuentes P,
Alberola Candel V (2011) Phase II trial of oxaliplatin and capecitabine after
progression to first-line chemotherapy in androgen-independent prostate cancer
patients. Am J Clin Oncol 34: 155–159.
7. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, et al. (2005)
Nonapical and cytoplasmic expression of interleukin-8, CXCR1 and CXCR2
correlates with cell proliferation and microvessel density in prostate cancer. Clin
Cancer Res 11: 4117–412.
8. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, et al. (2005)
Expression of interleukin-8 gene in radical prostatectomy specimens is associated
with advanced pathologic stage. Prostate 64: 40–9.
9. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, et al. (2007) HIF-1 and
NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression
promotes survival in hypoxic prostate cancer cells. Oncogene 26: 7333–45.
10. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, et al. (2008a)
Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signalling
in metastatic prostate cancer cells confers resistance to oxaliplatin through
potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J
Pharm Exp Ther 327: 746–759.
11. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ (2008b) Interleukin-
8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through
transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther
7: 2649–2661.
12. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, et al. (2007) Interleukin-8
is a molecular determinant of androgen-independence and progression in
prostate cancer. Cancer Res 67: 6854–6862.
13. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, et al. (2008) Interleukin-
8 signaling promotes androgen-independent proliferation of prostate cancer cells
via induction of androgen receptor expression and activation. Carcinogenesis.
29: 1148–1156.
14. MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, et al. (2007)
Interleukin-8 signaling promotes translational regulation of cyclin D1 in
androgen-independent prostate cancer cells. Mol Cancer Res 5: 737–748.
15. Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, et al. (2009) Inhibition
of constitutive and CXC-chemokine-induced NF-kappaB activity potentiates
ansamycin-based Hsp90-inhibitor cytotoxicity in castrate-resistant prostate
cancer cells. Br J Cancer 101: 1620–1629.
16. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979)
Establishment and characterization of a human prostate adenocarcinoma cell
line (PC-3). Invest Urol 17: 16–23.
17. Adjei AA (2004) Pemetrexed (ALIMTA): a novel multitargeted antineoplastic
agent. Clin Cancer Res 10: 4276s–4280s.
18. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, et al. (1995)
Thymidylate synthase gene and protein expression correlate and are associated
with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer
Res 55: 1407–12.
19. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, et al. (2000)
Colorectal tumors responding to 5-fluorouracil have low gene expression levels
of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine
phosphorylase. Clin Cancer Res 6: 1322–7.
20. Veltri RW, Miller MC, Partin AW, Poole EC, O’Dowd GJ (1999) Interleukin-8
serum levels in patients with benign prostatic hyperplasia and prostate cancer.
Cancer 91: 2322–2328.
21. Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, et al. (2009) A phase II
study of pemetrexed as second-line chemotherapy for the treatment of metastatic
castrate-resistant prostate cancer (CRPC)- Hoosier Oncology Group GU03-67.
Ann Oncol 20: 1971–1976.
22. Caffo O, Fratino L, Barbieri R, Perin A, Martini T, et al. (2011) Pemetrexed as
second-line chemotherapy for castrate-resistant prostate cancer after docetaxel
failure: results from a phase II study. Urol Oncol, epub ahead of print Jul 29.
23. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, et al. (2002)
Expression of interleukin 8 and not parathyroid hormone-related protein by
human breast cancer cells correlates with bone metastasis in vivo. Cancer Res.
62: 5571–5579.
24. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, et al. (2011) Interleukin-8
is associated with proliferation, migration, angiogenesis and chemosensitivity.
Int J Cancer 128: 2038–49.
25. Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, et al. (2003)
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-
fluorouracil in hormone refractory metastatic prostate cancer patients. Ann
Oncol 14: 1291–8.
CXCL8 Signalling Antagonizes TS-Targeted Agents
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36545